Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11

Cancer Letters

Volumn 127, Issue 1-2, 1998, Pages 99-106

  Sadzuka, Yasuyuki ^a   Hirotsu, Sachiyo ^a   Hirota, Sadao ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Antitumor activity; CPT 11; Liposome; Side toxicity; SN 38; Tissue distribution

Indexed keywords

DRUG METABOLITE; IRINOTECAN; LIPOSOME; MACROGOL; PRODRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ENTEROPATHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE; BODY WEIGHT; CAMPTOTHECIN; CARCINOMA, EHRLICH TUMOR; DRUG CARRIERS; FECES; LIPOSOMES; LIVER; MALE; MICE; NEOPLASM TRANSPLANTATION; WATER;

ANIMALIA;

EID: 0032523735     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00031-7     Document Type: Article

References (21)

1. Negoro S., Fukuoka M., Niitani H., Suzuki A., Nakabayashi T., Kimura M., Motomiya M., Kurita Y., Hasegawa K., Taguchi T. A phase I study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Jpn. J. Cancer Chemother. 18:1991;1013-1019.
2. Kudoh S., Takada M., Masuda N., Nakagawa K., Itoh K. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res. 84:1993;203-207.
3. Nishimura G., Satou T., Yoshimitsu Y., Kurosaka Y., Fujimura T. Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer. Jpn. J. Cancer Chemother. 22:1995;93-97.
4. Ohno R., Okada K., Masaoka T., Kuramoto A., Arima T., Yoshida Y., Ariyoshi H., Ichimaru M., Sakai Y., Oguro M., Ito Y., Morishima Y., Yokomaku S., Ota K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8:1990;1907-1912.
5. Bleiberg H., Cvitkovic E. Characterization and clinical management of CPT-11-induced adverse events. Eur. J. Cancer. 32:1996;S18-S23.
6. Sadzuka Y., Nakai S., Miyagishima A., Nozawa Y., Hirota S. The effect of dose on the distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes. J. Drug Targeting. 3:1995;31-37.
7. Sadzuka Y., Nakai S., Miyagishima A., Nozawa Y., Hirota S. Effects of administered route on tissue distribution and antitumor activity of polyethyleneglycol-coated liposomes containing adriamycin. Cancer Lett. 111:1997;77-86.
8. Sadzuka Y., Hirota S. Physical properties and tissue distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes. Adv. Drug Deliv. Rev. 24:1997;257-263.
9. H. Terada, A. Tsuji, Membrane Transport and Tissue Targeting of Drugs, Hirokawa, Tokyo, 1991, pp. 545-551.
10. Kono A., Hara Y. Conversion of CPT-11 into SN-38 in human tissues. Jpn. J. Cancer Chemother. 18:1991;2175-2178.
11. Gill P.S., Espina B.M., Muggia F., Cabriales S., Tulpule A., Esplin J.A., Liebman H.A., Forssen E., Ross M.E., Levine A.M. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 13:1995;996-1003.
12. Ohe Y., Sasaki Y., Shinkai T., Eguchi K., Tamura T., Kojima A., Kunikane H., Okamoto H., Karato A., Ohmatsu H., Kanzawa F., Saijo N. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84:1992;972-974.
13. Takasago K., Kasai Y., Kitano Y., Mori K., Kakihata K., Hirohashi M., Nonura M. Study of the mechanism on CPT-11 induced diarrhea. Folia Pharmacol. Jpn. 105:1995;447-460.
14. Mick R., Gupta E., Vokes E.E., Ratain M.J. Limited-sampling models for irinotecan pharmacokinetics-pharmadynamics: prediction of biliary index and intestinal toxicity. J. Clin. Oncol. 14:1996;2012-2019.
15. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ion across the lamellae of swollen phospholipids. J. Mol. Biol. 13:1965;238-252.
16. Sadzuka Y., Hirotsu S., Miyagishima A., Nozawa Y., Hirota S. The preparation and the tissue distribution of liposomal CPT-11. Drug Delivery System. 11:1996;419-426.
17. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of polyethylene glycol show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36.
18. Shimada K., Miyagishima A., Sadzuka Y., Nozawa Y., Hirota S. Determination of the thickness of fixed aqueous layer around the polyethyleneglycol-coated liposomes. J. Drug Targeting. 3:1995;283-289.
19. Araki E., Ishikawa M., Iigo M., Koide T., Itabashi M. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 84:1993;697-702.
20. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., Ratain M.J. Metabolic fate of irinotecan in humans. Correlation of glucuronidation with diarrhea. Cancer Res. 54:1994;3723-3725.
21. Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai M., Yokoi T., Kamataki T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56:1996;3752-3757.